Fibocom Announces Multiple Next-Gen 5G NR Modules to 3GPP R16 Standard at MWC Shanghai 2021
Fibocom (Stock Code: 300638), a leading provider of cellular embedded wireless module solutions for the Internet of Things (IoT), announced the world-wide launch of the next generation 5G NR modules compliant with the 3GPP R16 standard during Mobile World Congress Shanghai 2021 (MWCS21). The new launch includes FM160 and FG160 5G module series of Sub-6GHz frequency range, as well as FM160W and FG160W series of mmWave range.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005973/en/
Fibocom Next-Gen 5G Modules (Photo: Fibocom)
Product video on YouTube:
https://www.youtube.com/watch?v=Wg0nE1WtoBM
The new 5G NR module series is based on the newly-announced Qualcomm® Snapdragon™ X65 and X62 5G Modem-RF Systems and delivers enhanced mobile broadband and high-reliability, low-latency wireless services for IIoT (Industrial IoT), FWA ( Fixed Wireless Access), 4K/8K live streaming, telemedicine, private 5G networks, and other mass data scenarios by supporting lightening data transmission speeds up to 10Gbps, three modes of CA （Carrier Aggregation）combinations including FDD+TDD, TDD+TDD, FDD+FDD, global frequency bands of 5G SA/ENDC/4G, dynamic antenna tuning, and next-generation software algorithm.
“Qualcomm Technologies has closely worked with Fibocom over years to support innovation and deep collaboration in a multitude of IoT segments requiring high-performance, high-reliability across industries”, said Gang Sun, vice president, product marketing, Qualcomm International (Shanghai) Co., Ltd. “Based on the advantages of our fourth-generation 5G modem-to-antenna solution in data speeds, coverage, upgradeable architecture and power efficiency, we look forward to further seeing how Fibocom’s strong experience in IoT combined with Qualcomm Technologies’ advanced technologies brings 5G benefits to more consumers and industries.”
Tiger Ying, CEO of Fibocom, said, “The fourth industrial revolution has made digital production the currency of modern business models. 5G will bring possibilities to IoT and industrial digitalization beyond our imagination. Government utilities and enterprises are facing insufficient automation and reliable remote management to enhance operating efficiency and safety. Our new 5G series based on Qualcomm Technologies’ latest Snapdragon X65 and X62 5G Modem-RF Systems, is designed to answer the pain points, setting a new benchmark for high-speed, low latency, and reliable wireless communications services, and helping us become the trusted choice for 5G IoT solutions.”
Remarks:
Qualcomm and Snapdragon are trademarks or registered trademarks of Qualcomm Incorporated.
Qualcomm Snapdragon is a product of Qualcomm Technologies, Inc. and/or its subsidiaries
About Fibocom Wireless Inc.
Founded in 1999, Fibocom is a leading global provider of IoT (Internet of Things) wireless solution and wireless communication modules. We are committed to bringing reliable, accessible, secure, and intelligent wireless solutions to every IoT application scenario for the increasingly digitalized industries and enriched smart life of the whole society. In 2017, Fibocom become the first stock-listed (Stock Code: 300638) wireless module provider in China.
We provide technically advanced and high-performance 5G, 4G, NB-IoT/eMTC, 3G, and 2G, smart, auto-grade, GNSS, Wi-Fi/BT wireless modules. By technically embedding Fibocom’s wireless solutions into IoT devices that will become smart and remotely manageable with stable data transmission between devices and operation center, we empower the intelligent future of all industries that mainly include smart retail, ACPC (Always Connected PC), industry 4.0, smart grid, smart homes, smart agriculture, smart cities, telemedicine, metering, smart security surveillance, and the intelligently connected cars, etc. We have many long-term industry customers including Fortune Global 500 enterprises, which is an important driven power of our fast development.
Fibocom is headquartered in Shenzhen, China, and has R&D centers in both Shenzhen and Xi'an. We are globally located with more than 30 subsidiaries and regional operation centers in China, Americas, EMEA, and Asia Pacific Regions. Currently, we have more than 1000 global employees, and provide products and services in more than 100 countries and regions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005973/en/
Contact information
Media:
Ellie Yuan
info@fibocom.com
www.fibocom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release
Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release
3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad
Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 08:00:00 EET | Press release
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom